- Home
- AXGN vs AGEN Comparison
AXGN vs AGEN Comparison
Compare AXGN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXGN
- AGEN
- Stock Information
- Founded
- AXGN N/A
- AGEN 1994
- Country
- AXGN United States
- AGEN United States
- Employees
- AXGN N/A
- AGEN N/A
- Industry
- AXGN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXGN Health Care
- AGEN Health Care
- Exchange
- AXGN Nasdaq
- AGEN Nasdaq
- Market Cap
- AXGN 584.7M
- AGEN 97.7M
- IPO Year
- AXGN N/A
- AGEN 2000
- Fundamental
- Price
- AXGN $13.15
- AGEN $4.50
- Analyst Decision
- AXGN Strong Buy
- AGEN Buy
- Analyst Count
- AXGN 4
- AGEN 3
- Target Price
- AXGN $15.00
- AGEN $10.00
- AVG Volume (30 Days)
- AXGN 370.0K
- AGEN 346.0K
- Earning Date
- AXGN 11-05-2024
- AGEN 11-05-2024
- Dividend Yield
- AXGN N/A
- AGEN N/A
- EPS Growth
- AXGN N/A
- AGEN N/A
- EPS
- AXGN N/A
- AGEN N/A
- Revenue
- AXGN $173,482,000.00
- AGEN $159,630,000.00
- Revenue This Year
- AXGN $18.49
- AGEN N/A
- Revenue Next Year
- AXGN $12.78
- AGEN $0.04
- P/E Ratio
- AXGN N/A
- AGEN N/A
- Revenue Growth
- AXGN 17.26
- AGEN 60.67
- 52 Week Low
- AXGN $3.45
- AGEN $4.18
- 52 Week High
- AXGN $15.23
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- AXGN 44.12
- AGEN 40.31
- Support Level
- AXGN $13.08
- AGEN $4.50
- Resistance Level
- AXGN $15.23
- AGEN $4.78
- Average True Range (ATR)
- AXGN 0.65
- AGEN 0.29
- MACD
- AXGN -0.17
- AGEN 0.02
- Stochastic Oscillator
- AXGN 12.97
- AGEN 30.77
About AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).